Rivunatpagene miziparvovec

米哌雷帕基

Report date: 2023/10/26 16:54:09

Base Information

Drug NameRivunatpagene miziparvovec
Drug Alias NameUX-701
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV9 vector
Mechanisms of ActionCopper-transporting ATPase replacements
TargetsCopper-transporting ATPase
Therapy Area/IndicationsHepatolenticular Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesPortugal +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUltragenyx Pharmaceutical Inc
China Registration ClassN/A

Develop Information

Active CompaniesUltragenyx Pharmaceutical Inc
Inactive CompaniesN/A
Active IndicationsHepatolenticular Degeneration
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A